Trial Profile
A dose-range finding study with the optimized formulation of tenofovir exalidex in HBV patients
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 23 Aug 2019
Price :
$35
*
At a glance
- Drugs Tenofovir exalidex (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; Pharmacokinetics
- 28 Jun 2018 New trial record
- 21 Jun 2018 According to a ContraVir Pharmaceuticals media release, the company is ready to initiate dosing in this trial.